Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitoxantrone liposome + CLAG study in relapsed/refractory acute myeloid leukemia
ChiCTR2400086291Phase 4Not yet recruiting
- Sponsor
- Xinqiao Hospital
- Start
- Jun 2024
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mitoxantrone-liposome, cladribine, cytarabine and granulocyte colony-stimulating factor in acute myeloid leukemia (AML), sponsored by Xinqiao Hospital. Primary endpoint: Composite complete remission rate. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
mitoxantrone-liposomecladribinecytarabinegranulocyte colony-stimulating factor
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2400086291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086291.